STOCK TITAN

[8-K] W.R. Berkley Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) – Form 4 filing, 21 Jul 2025. Sr. VP, General Counsel & Secretary Meredith W. Cook reported a tax-related share withholding transaction on 18 Jul 2025.

  • Transaction type: Code F (shares withheld to satisfy taxes on vested restricted stock).
  • Securities affected: 2,071 common shares at an implied price of $66.30, total ≈ $0.14 million.
  • Post-transaction holding: Cook now directly owns 76,874 common shares.
  • Derivative positions: No derivative transactions reported; prior option/RSU holdings unchanged.

The filing reflects routine tax withholding rather than an open-market sale. Cook retains >97% of her pre-vesting equity stake, signalling continued alignment with shareholders. No impact on the company’s operations, earnings outlook or governance structure was disclosed.

ANI Pharmaceuticals (ANIP) – Deposito Form 4, 21 lug 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha comunicato una transazione di ritenuta azionaria per motivi fiscali il 18 lug 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte sulle azioni vincolate maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di 66,30 $, per un totale di circa 0,14 milioni di dollari.
  • Detenzione post-transazione: Cook detiene ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivative: Nessuna transazione derivata segnalata; le precedenti opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine e non una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-vesting, segnalando un continuo allineamento con gli azionisti. Non sono stati comunicati impatti sulle operazioni aziendali, sulle previsioni degli utili o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) – Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones por motivos fiscales el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2.071 acciones comunes a un precio implícito de $66.30, total ≈ $0.14 millones.
  • Tenencia después de la transacción: Cook posee ahora directamente 76.874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las opciones/RSU previas permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria antes del vesting, lo que indica un alineamiento continuo con los accionistas. No se divulgaron impactos en las operaciones de la empresa, perspectivas de ganancias o estructura de gobierno.

ANI Pharmaceuticals (ANIP) – 2025년 7월 21일 Form 4 제출. 수석 부사장 겸 법률 고문 및 비서인 Meredith W. Cook가 2025년 7월 18일 세금 관련 주식 원천징수 거래를 보고했습니다.

  • 거래 유형: 코드 F (취득 제한 주식에 대한 세금 납부를 위한 주식 원천징수).
  • 영향을 받은 증권: 암시 가격 $66.30에 2,071 보통주, 총 약 $0.14백만.
  • 거래 후 보유 주식: Cook는 현재 직접 76,874 보통주를 보유 중입니다.
  • 파생상품 포지션: 파생상품 거래 보고 없음; 이전 옵션/RSU 보유는 변동 없음.

이번 제출은 공개 시장 매도가 아닌 일상적인 세금 원천징수를 반영합니다. Cook는 취득 전 지분의 97% 이상을 유지하며 주주와의 지속적인 이해관계를 나타냅니다. 회사 운영, 수익 전망 또는 거버넌스 구조에 미치는 영향은 공개되지 않았습니다.

ANI Pharmaceuticals (ANIP) – Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à l’impôt le 18 juillet 2025.

  • Type de transaction : Code F (actions retenues pour satisfaire l’impôt sur les actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit environ 0,14 million de dollars.
  • Position après transaction : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions dérivées : Aucune transaction dérivée signalée ; les options/RSU précédentes restent inchangées.

Le dépôt reflète une retenue fiscale de routine et non une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, témoignant d’un alignement continu avec les actionnaires. Aucun impact sur les opérations, les perspectives de bénéfices ou la gouvernance de l’entreprise n’a été divulgué.

ANI Pharmaceuticals (ANIP) – Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Sekretärin, meldete am 18. Juli 2025 eine steuerbedingte Aktieneinbehaltstransaktion.

  • Transaktionstyp: Code F (Aktien einbehalten zur Begleichung von Steuern auf erworbene Restricted Stocks).
  • Betroffene Wertpapiere: 2.071 Stammaktien zu einem impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach der Transaktion: Cook besitzt nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; vorherige Optionen/RSUs unverändert.

Die Meldung spiegelt eine routinemäßige Steuerabführung wider und keinen Verkauf am freien Markt. Cook behält über 97 % ihres Anteils vor dem Vesting, was auf eine weiterhin starke Ausrichtung auf die Aktionäre hinweist. Keine Auswirkungen auf den Geschäftsbetrieb, die Gewinnprognose oder die Governance-Struktur wurden bekannt gegeben.

Positive
  • Executive retains 76,874 shares, indicating continued equity exposure and alignment with shareholders.
Negative
  • 2,071 shares were disposed of (withheld for taxes), mildly increasing share float, though impact is immaterial.

Insights

TL;DR: Routine tax withholding; negligible market impact.

The Code F disposition simply covers payroll taxes on 4,820 vested RSUs. At ≈ $137k, it is immaterial relative to ANIP’s average daily dollar volume and the executive’s remaining 76.9k-share stake. Because there was no discretionary sale, the signal value is neutral. Investors should not read this as a change in insider sentiment. Impact on float and EPS is de minimis.

ANI Pharmaceuticals (ANIP) – Deposito Form 4, 21 lug 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha comunicato una transazione di ritenuta azionaria per motivi fiscali il 18 lug 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte sulle azioni vincolate maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di 66,30 $, per un totale di circa 0,14 milioni di dollari.
  • Detenzione post-transazione: Cook detiene ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivative: Nessuna transazione derivata segnalata; le precedenti opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine e non una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-vesting, segnalando un continuo allineamento con gli azionisti. Non sono stati comunicati impatti sulle operazioni aziendali, sulle previsioni degli utili o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) – Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones por motivos fiscales el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2.071 acciones comunes a un precio implícito de $66.30, total ≈ $0.14 millones.
  • Tenencia después de la transacción: Cook posee ahora directamente 76.874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las opciones/RSU previas permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria antes del vesting, lo que indica un alineamiento continuo con los accionistas. No se divulgaron impactos en las operaciones de la empresa, perspectivas de ganancias o estructura de gobierno.

ANI Pharmaceuticals (ANIP) – 2025년 7월 21일 Form 4 제출. 수석 부사장 겸 법률 고문 및 비서인 Meredith W. Cook가 2025년 7월 18일 세금 관련 주식 원천징수 거래를 보고했습니다.

  • 거래 유형: 코드 F (취득 제한 주식에 대한 세금 납부를 위한 주식 원천징수).
  • 영향을 받은 증권: 암시 가격 $66.30에 2,071 보통주, 총 약 $0.14백만.
  • 거래 후 보유 주식: Cook는 현재 직접 76,874 보통주를 보유 중입니다.
  • 파생상품 포지션: 파생상품 거래 보고 없음; 이전 옵션/RSU 보유는 변동 없음.

이번 제출은 공개 시장 매도가 아닌 일상적인 세금 원천징수를 반영합니다. Cook는 취득 전 지분의 97% 이상을 유지하며 주주와의 지속적인 이해관계를 나타냅니다. 회사 운영, 수익 전망 또는 거버넌스 구조에 미치는 영향은 공개되지 않았습니다.

ANI Pharmaceuticals (ANIP) – Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à l’impôt le 18 juillet 2025.

  • Type de transaction : Code F (actions retenues pour satisfaire l’impôt sur les actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit environ 0,14 million de dollars.
  • Position après transaction : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions dérivées : Aucune transaction dérivée signalée ; les options/RSU précédentes restent inchangées.

Le dépôt reflète une retenue fiscale de routine et non une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, témoignant d’un alignement continu avec les actionnaires. Aucun impact sur les opérations, les perspectives de bénéfices ou la gouvernance de l’entreprise n’a été divulgué.

ANI Pharmaceuticals (ANIP) – Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Sekretärin, meldete am 18. Juli 2025 eine steuerbedingte Aktieneinbehaltstransaktion.

  • Transaktionstyp: Code F (Aktien einbehalten zur Begleichung von Steuern auf erworbene Restricted Stocks).
  • Betroffene Wertpapiere: 2.071 Stammaktien zu einem impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach der Transaktion: Cook besitzt nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; vorherige Optionen/RSUs unverändert.

Die Meldung spiegelt eine routinemäßige Steuerabführung wider und keinen Verkauf am freien Markt. Cook behält über 97 % ihres Anteils vor dem Vesting, was auf eine weiterhin starke Ausrichtung auf die Aktionäre hinweist. Keine Auswirkungen auf den Geschäftsbetrieb, die Gewinnprognose oder die Governance-Struktur wurden bekannt gegeben.

0000011544false00000115442025-07-212025-07-210000011544wrb:SubordinatedDebenturesDue20585.70Member2025-07-212025-07-210000011544wrb:SubordinatedDebenturesDue20595.10Member2025-07-212025-07-210000011544wrb:SubordinatedDebenturesDue2060425Member2025-07-212025-07-210000011544wrb:SubordinatedDebenturesDue20614125Member2025-07-212025-07-21
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2025
Commission File Number
1-15202


     W. R. BERKLEY CORPORATION     
(Exact name of registrant as specified in its charter)
Delaware22-1867895
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)
  
475 Steamboat RoadGreenwichConnecticut06830
(Address of principal executive offices)(Zip Code)
(203)629-3000
(Registrant’s telephone number, including area code)
None
Former name, former address and former fiscal year, if changed since last report.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class Trading Symbol Name of Each Exchange
on Which Registered
Common Stock, par value $.20 per share WRB New York Stock Exchange
5.700% Subordinated Debentures due 2058WRB-PENew York Stock Exchange
5.100% Subordinated Debentures due 2059WRB-PFNew York Stock Exchange
4.250% Subordinated Debentures due 2060WRB-PGNew York Stock Exchange
4.125% Subordinated Debentures due 2061WRB-PHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).    Emerging growth company         


W. R. Berkley Corporation         2

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         


W. R. Berkley Corporation         3

Item 2.02 Results of Operations and Financial Condition.
Reference is made to the press release of W. R. Berkley Corporation (the “Company”) relating to the announcement of the Company’s results of operations for the second quarter of 2025. The press release was issued on July 21, 2025. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information contained herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.


W. R. Berkley Corporation         4

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press Release dated July 21, 2025





W. R. Berkley Corporation         5



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

W. R. BERKLEY CORPORATION




By: /s/ Richard M. Baio
Name:Richard M. Baio
Title:Executive Vice President -
Chief Financial Officer




        


Date: July 21, 2025


W. R. Berkley Corporation         6

EXHIBIT INDEX


Exhibit:
99.1         Press Release dated July 21, 2025





FAQ

What did ANIP insider Meredith Cook report in the Form 4 filed 21-Jul-2025?

She disclosed 2,071 shares of ANIP common stock were withheld on 18-Jul-2025 to pay taxes on vested RSUs.

How many ANIP shares does Meredith Cook now own?

After the transaction, she directly holds 76,874 common shares.

Was this an open-market sale of ANIP stock?

No. The Code F designation indicates shares were withheld by the company for tax purposes, not sold on the market.

Does the Form 4 affect ANIP’s earnings or guidance?

No operational or financial guidance was provided; the filing only details insider share movements.

Is the 2,071-share disposition material to ANIP shareholders?

At ≈ $137k and <0.01% of shares outstanding, the impact is not material to valuation or float.
W.R Berkley

NYSE:WRB

WRB Rankings

WRB Latest News

WRB Stock Data

26.35B
285.31M
24.33%
69.4%
2.28%
Insurance - Property & Casualty
Fire, Marine & Casualty Insurance
Link
United States
GREENWICH